4.7 Article

Use of bladder antimuscarinics is associated with an increased risk of dementia: a retrospective population-based case-control study

期刊

SCIENTIFIC REPORTS
卷 11, 期 1, 页码 -

出版社

NATURE PORTFOLIO
DOI: 10.1038/s41598-021-84229-2

关键词

-

资金

  1. Taiwan Ministry of Health and Welfare Clinical Trial Center [MOHW109-TDU-B-212-114004]
  2. China Medical University Hospital, Academia Sinica Stroke Biosignature Project [BM10701010021]
  3. MOST Clinical Trial Consortium for Stroke [MOST 108-2321-B-039-003]
  4. TsengLien Lin Foundation, Taichung, Taiwan
  5. Katsuzo and Kiyo Aoshima Memorial Funds, Japan

向作者/读者索取更多资源

This study used data from the Taiwan National Health Insurance Research Database to investigate the association between bladder antimuscarinic use and dementia risk in patients aged 55 years or older. The study found that Taiwanese patients who used bladder antimuscarinics for more than 1 year had a significantly higher risk of developing dementia compared to those who did not use this treatment. Additionally, the risk of dementia increased proportionally with higher doses of antimuscarinics and longer duration of use.
The association between bladder antimuscarinic use and dementia development is unclear. We used data from the Taiwan National Health Insurance Research Database to determine the association between the exposure dose and duration of bladder antimuscarinics and the subsequent dementia risk. We enrolled participants aged 55 years or more and defined a dementia cohort (International Classification of Diseases, Ninth Revision, Clinical Modification codes 290, 294.1, and 331.0). We used a propensity score matching method, and randomly enrolled two controls without dementia. We evaluated dementia risk with respect to the exposure dose and duration of treatment with seven bladder antimuscarinics (oxybutynin, propiverine, tolterodine, solifenacin, trospium, darifenacin, and fesoterodine) used for at least 1 year before the index date, after adjusting for age, sex, comorbidities, and medications. The dementia risk was 2.46-fold (95% confidence interval: 2.22-2.73) higher in Taiwanese patients who used bladder antimuscarinics for >= 1 year than in those who were not exposed to this treatment. The risk proportionally increased with increasing doses of antimuscarinics for less than 4 years. Taiwanese patients aged 55 years or more on bladder antimuscarinics exhibited a higher risk of dementia. Additional studies in other countries are required to determine whether this result is valid worldwide.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据